Clinical trials: Relapsed/ Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available…
- Trial name
- NCT06825845
- Testing
- Zevorcabtagene Autoleucel
- Volunteers
- 1,500 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Note: The study data was transferred to zr pharma\& following the divestment of panobinostat to pharma\&. Prior to study completion under the sponsorship of Secura Bio, the study was initiated and conducted in part under the…
- Trial name
- PANORAMA_3 (NCT02654990)
- Testing
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Where
- 80 sites in United States, Australia and 20 more
- Volunteers
- 248 people
- Sponsor
- pharmaand GmbH
Multiple Myeloma and Other Plasma Cell Neoplasms
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the…
- Trial name
- NCT07529782
- Testing
- HDP-101
- Where
- 5 sites in China
- Volunteers
- 15 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Multiple Myeloma, Chronic Lymphocytic Leukaemia
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
The aim of this study is to determine the safety, tolerability and dose-limiting toxicities of KW-2478 and to determine the Maximum Tolerated Dose and recommended Phase II dose for patients with relapsed/refractory MM, CLL or…
- Conditions
- Multiple Myeloma, Chronic Lymphocytic Leukaemia, B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT00457782
- Testing
- KW-2478
- Where
- 6 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or…
- Trial name
- NCT06433947
- Testing
- OPN-6602, Dexamethasone
- Where
- 12 sites in United States
- Volunteers
- 130 people
- Sponsor
- Opna Bio LLC
Multiple Myeloma
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.
- Trial name
- NCT03379584
- Testing
- SGN-CD48A
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in…
- Trial name
- NCT02076009
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 145 sites in United States, Australia and 16 more
- Volunteers
- 569 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma (RRMM)
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT07715630
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
This is a phase 2/3, open label trial for patients with relapsed-refractory multiple myeloma. Study agent is tanespimycin (KOS-953), at three different dose levels in combination with a fixed dose of bortezomib.
- Trial name
- TIME-2 (NCT00514371)
- Testing
- tanespimycin, Bortezomib
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
Multiple Myeloma
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT05299424
- Testing
- CM336_group 1, CM336_group 2a, CM336_group 2b
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Relapsed/Refractory Multiple Myeloma
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011…
- Trial name
- CaMMouflage (NCT05722418)
- Testing
- CB-011
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199…
- Trial name
- NCT01794520
- Testing
- Venetoclax, Dexamethasone
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- AbbVie
Multiple Myeloma
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT02011113
- Testing
- Pomalidomide, Dexamethasone
- Where
- 14 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Relapsed and/or Refractory Multiple Myeloma
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
This will be a Phase 1 Open-Label, dose escalation of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT04017130
- Testing
- MT-0169
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Molecular Templates, Inc.
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered…
- Trial name
- NCT05259839
- Testing
- Etentamig, Dexamethasone, Lenalidomide
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 283 people
- Sponsor
- AbbVie
Multiple Myeloma
Study of ENMD-2076 in Patients With Multiple Myeloma
Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00806065
- Testing
- ENMD-2076
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- CASI pharmaceuticals, Inc.
Relapsed or Refractory Multiple Myeloma
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
This is a single arm, single center clinical study evaluating the safety and efficacy of CAR-T treatment for relapsed or refractory multiple myeloma.
- Trial name
- NCT06068400
- Testing
- BCMA/GPRC5D dual CAR-T
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00085345
- Testing
- arsenic trioxide, ascorbic acid, melphalan
- Where
- 19 sites in United States
- Sponsor
- Oncotherapeutics